StockpollyBeta
Get App
Popularity #4,081Earnings in 2d
ENLV · NASDAQ · Biotechnology

Enlivex (ENLV)

Develops Allocetra for knee osteoarthritis and manages a RAIN-centered digital-asset treasury.

$0.6274
vs last close−0.02 (−2.94%)

In millions of USD, except per-share figures

In millionsQ1 FY23Mar 2023Q2 FY23Jun 2023Q3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025
Cost of revenue000000000000
Gross profit000000000000
7761043364326
Research & development554432233213
221111121113
General & administrative221111121113
Other expenses000500000000
Operating income−7−7−6−10−4−3−3−6−4−3−3−6
000100100101,632
Interest income000000100100
Interest expense000000000000
Other non-operating income000−400000000
Income before tax−7−7−6−9−4−3−3−5−3−2−21,626
Income tax expense00000000000383
Net income from continuing operations−7−7−6−9−4−3−3−5−3−2−21,243
Net income−7−7−6−9−4−3−3−5−3−2−21,243
EPS, basic−$0.41−$0.37−$0.32−$7.35−$3.30−$2.40−$1.80−$3.60−$2.40−$1.17−$1.38$410.25
EPS, diluted−$0.41−$0.37−$0.32−$7.35−$3.30−$2.40−$1.80−$3.60−$2.40−$1.17−$1.38$386.85
Weighted average shares, basic191919111111223
Weighted average shares, diluted191919111111223
EBITDA−7−6−5−6−4−3−3−5−3−3−2−6
Depreciation & amortization000000000000
EBIT−7−7−6−6−4−3−3−5−4−3−2−6